LYEL vs. MAZE
LYEL (Lyell Immunopharma, Inc.) and MAZE (Maze Therapeutics, Inc) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past year, LYEL returned 4.45% vs 81.93% for MAZE. At a 0.22 correlation, their price movements are largely independent.
Performance
LYEL vs. MAZE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, LYEL achieves a -61.11% return, which is significantly lower than MAZE's -41.42% return.
LYEL
- 1D
- -8.28%
- 1M
- -42.59%
- YTD
- -61.11%
- 6M
- -52.59%
- 1Y
- 4.45%
- 3Y*
- -44.12%
- 5Y*
- —
- 10Y*
- —
MAZE
- 1D
- -4.45%
- 1M
- -8.31%
- YTD
- -41.42%
- 6M
- -41.81%
- 1Y
- 81.93%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
LYEL vs. MAZE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | |
|---|---|---|
LYEL Lyell Immunopharma, Inc. | -61.11% | 160.71% |
MAZE Maze Therapeutics, Inc | -41.42% | 159.75% |
Correlation
The correlation between LYEL and MAZE is 0.23, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.23 |
Correlation (All Time) Calculated using the full available price history since Feb 3, 2025 | 0.22 |
Fundamentals
LYEL:
$261.86M
MAZE:
$1.31B
LYEL:
-$13.68
MAZE:
-$2.63
LYEL:
0.96
MAZE:
3.83
LYEL:
$31.00K
MAZE:
$0.00
LYEL:
-$11.51M
MAZE:
-$1.15M
LYEL:
-$140.21M
MAZE:
-$126.66M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
LYEL vs. MAZE — Risk / Return Rank
LYEL
MAZE
LYEL vs. MAZE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Lyell Immunopharma, Inc. (LYEL) and Maze Therapeutics, Inc (MAZE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| LYEL | MAZE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.87 | ||
| Sortino ratioReturn per unit of downside risk | -1.24 | ||
| Omega ratioGain probability vs. loss probability | 1.08 | 1.27 | -0.19 |
| Calmar ratioReturn relative to maximum drawdown | 0.06 | 1.55 | -1.48 |
| Martin ratioReturn relative to average drawdown | 0.14 | 3.51 | -3.37 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| LYEL | MAZE | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.05 | 0.92 | -0.87 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.52 | 0.39 | -0.91 |
Drawdowns
LYEL vs. MAZE - Drawdown Comparison
The maximum LYEL drawdown since its inception was -97.83%, which is greater than MAZE's maximum drawdown of -53.18%. Use the drawdown chart below to compare losses from any high point for LYEL and MAZE.
Loading charts...
Drawdown Indicators
| LYEL | MAZE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.83% | -53.18% | -44.65% |
Max Drawdown (1Y)Largest decline over 1 year | -68.99% | -53.18% | -15.81% |
Max Drawdown (3Y)Largest decline over 3 years | -89.90% | — | — |
Current DrawdownCurrent decline from peak | -96.67% | -53.18% | -43.49% |
Average DrawdownAverage peak-to-trough decline | -79.26% | -20.31% | -58.95% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 30.99% | 23.40% | +7.59% |
Volatility
LYEL vs. MAZE - Volatility Comparison
Lyell Immunopharma, Inc. (LYEL) has a higher volatility of 26.47% compared to Maze Therapeutics, Inc (MAZE) at 13.08%. This indicates that LYEL's price experiences larger fluctuations and is considered to be riskier than MAZE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| LYEL | MAZE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 26.47% | 13.08% | +13.39% |
Volatility (6M)Calculated over the trailing 6-month period | 58.36% | 56.48% | +1.88% |
Volatility (1Y)Calculated over the trailing 1-year period | 85.52% | 89.63% | -4.11% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 94.51% | 94.97% | -0.46% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 94.51% | 94.97% | -0.46% |
Dividends
LYEL vs. MAZE - Dividend Comparison
Neither LYEL nor MAZE has paid dividends to shareholders.
Financials
LYEL vs. MAZE - Financials Comparison
This section allows you to compare key financial metrics between Lyell Immunopharma, Inc. and Maze Therapeutics, Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
LYEL and MAZE have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
LYEL has higher volatility (26.47%) compared to MAZE (13.08%). In terms of maximum drawdown, LYEL dropped -97.83% vs MAZE's -53.18%.
MAZE currently has the higher Sharpe Ratio (0.92 vs 0.05), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for LYEL and MAZE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer